Literature DB >> 34410594

Sclerosing Polycystic Adenoma: Conclusive Clinical and Molecular Evidence of Its Neoplastic Nature.

Juan C Hernandez-Prera1, Daryoush Saeed-Vafa2, Amin Heidarian3, Kathleen Gewandter4, Kristen Otto5, Bruce M Wenig2.   

Abstract

Sclerosing polycystic adenosis, initially considered a non-neoplastic salivary gland lesion and classified as such in the 2017 WHO Classification of Head and Neck Tumors, has been the subject of controversy regarding its possible neoplastic nature. The reporting of recurrent PI3K pathway alteration represents evidence to support these lesions as being neoplastic and more appropriately referred to as sclerosing polycystic adenoma (SPA). Herein, we provide additional evidence that supports the classification of SPA as a true neoplasm. Eight cases of SPA were identified in our database and consultation files. All cases were subjected to PTEN immunohistochemistry (IHC) and next-generation sequencing (NGS). In addition, one patient underwent genetic counseling and germline testing. The cases included 5 men and 3 women with a mean age of 41 years (range 11-78) and all tumors arose in the parotid gland. One patient had multiple recurrences over a period of 2 years. Morphologically the tumors were circumscribed and characterized by an admixture of acini, ducts and cysts embedded in a fibrotic/sclerotic stroma. The cells lining the ducts and cysts showed variable granular, vacuolated, foamy and apocrine cytoplasmic features, as well as acinar cells contained intracytoplasmic brightly eosinophilic granules. The apocrine intraductal proliferations showed mild to moderate atypia in 6 cases. One case showed overt malignant morphology that ranged from intraductal carcinoma to invasive salivary duct carcinoma. Seven cases tested for PTEN IHC showed loss of nuclear expression in the acinar and ductal cells with retained PTEN expression in the myoepithelial cell and stroma. NGS detected PIK3CA or PIK3R1 genetic alterations in 7 cases, including a novel TFG-PIK3CA fusion. Coexisting PTEN mutations were seen in 4 cases, including in a patient with clinical stigmata of Cowden syndrome and confirmed by germline genetic testing. Our findings herein documented including recurrence of tumor, malignant transformation, high prevalence of PI3K pathway oncogenic alterations and the possible heretofore undescribed association with Cowden syndrome add support to classifying SPA as true neoplasms justifying their designation as adenoma, rather than adenosis.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cowden syndrome; PI3K pathway; PTEN; Sclerosing polycystic adenoma; Sclerosing polycystic adenosis

Mesh:

Substances:

Year:  2021        PMID: 34410594      PMCID: PMC9187789          DOI: 10.1007/s12105-021-01374-w

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN: 1936-055X


  60 in total

1.  Molecular characterization of apocrine salivary duct carcinoma.

Authors:  Simion I Chiosea; Lindsay Williams; Christopher C Griffith; Lester D R Thompson; Ilan Weinreb; Julie E Bauman; Alyssa Luvison; Somak Roy; Raja R Seethala; Marina N Nikiforova
Journal:  Am J Surg Pathol       Date:  2015-06       Impact factor: 6.394

Review 2.  The TET2 interactors and their links to hematological malignancies.

Authors:  Feng Pan; Ophelia Weeks; Feng-Chun Yang; Mingjiang Xu
Journal:  IUBMB Life       Date:  2015-06-22       Impact factor: 3.885

3.  Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.

Authors:  C Leal; R Henrique; P Monteiro; C Lopes; M J Bento; C P De Sousa; P Lopes; S Olson; M D Silva; D L Page
Journal:  Hum Pathol       Date:  2001-05       Impact factor: 3.466

4.  Sclerosing polycystic adenosis of parotid gland with dysplasia and ductal carcinoma in situ. Report of three cases with immunohistochemical and ultrastructural examination.

Authors:  A Skálová; M Michal; R H W Simpson; I Stárek; J Prádná; M Pfaltz
Journal:  Virchows Arch       Date:  2002-01       Impact factor: 4.064

5.  Invasive carcinoma arising from sclerosing polycystic adenosis of the salivary gland.

Authors:  Rita Canas Marques; Ana Félix
Journal:  Virchows Arch       Date:  2014-03-02       Impact factor: 4.064

6.  Salivary duct carcinoma in situ of the parotid gland.

Authors:  R H W Simpson; S Desai; S Di Palma
Journal:  Histopathology       Date:  2008-10       Impact factor: 5.087

7.  Primary cutaneous apocrine carcinoma: a clinico-pathologic analysis of 24 cases.

Authors:  Alistair Robson; Alexander J F Lazar; Jara Ben Nagi; Andrew Hanby; Wayne Grayson; Meora Feinmesser; Scott R Granter; Paul Seed; Carla L Warneke; Phillip H McKee; Eduardo Calonje
Journal:  Am J Surg Pathol       Date:  2008-05       Impact factor: 6.394

8.  Molecular Profiling of Salivary Gland Intraductal Carcinoma Revealed a Subset of Tumors Harboring NCOA4-RET and Novel TRIM27-RET Fusions: A Report of 17 cases.

Authors:  Alena Skálová; Tomas Vanecek; Emmanuelle Uro-Coste; Justin A Bishop; Ilan Weinreb; Lester D R Thompson; Stefano de Sanctis; Marco Schiavo-Lena; Jan Laco; Cécile Badoual; Thalita Santana Conceiçao; Nikola Ptáková; Martina Baněčkova; Marketa Miesbauerová; Michal Michal
Journal:  Am J Surg Pathol       Date:  2018-11       Impact factor: 6.394

9.  The landscape of kinase fusions in cancer.

Authors:  Nicolas Stransky; Ethan Cerami; Stefanie Schalm; Joseph L Kim; Christoph Lengauer
Journal:  Nat Commun       Date:  2014-09-10       Impact factor: 14.919

10.  Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer.

Authors:  Stephen E Lincoln; Robert L Nussbaum; Allison W Kurian; Sarah M Nielsen; Kingshuk Das; Scott Michalski; Shan Yang; Nhu Ngo; Amie Blanco; Edward D Esplin
Journal:  JAMA Netw Open       Date:  2020-10-01
View more
  1 in total

1.  Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Salivary Glands.

Authors:  Alena Skálová; Martin D Hyrcza; Ilmo Leivo
Journal:  Head Neck Pathol       Date:  2022-03-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.